Incyte Corporation $INCY Shares Newly Bought by Sigma Planning Corp

Sigma Planning Corp bought a new stake in Incyte Corporation (NASDAQ:INCY) during the third quarter, HoldingsChannel reports. The institutional investor bought 10,108 shares of the biopharmaceutical company’s stock, valued at approximately $1,227,000.

Several other institutional investors have also bought and sold shares of the company. BlackRock Inc. bought a new position in Incyte during the second quarter valued at $2,044,189,000. Wellington Management Group LLP lifted its stake in shares of Incyte by 9.5% during the 2nd quarter. Wellington Management Group LLP now owns 3,575,521 shares of the biopharmaceutical company’s stock valued at $405,321,000 after buying an additional 309,385 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Incyte by 10.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,975,544 shares of the biopharmaceutical company’s stock valued at $185,873,000 after buying an additional 187,354 shares in the last quarter. Pacer Advisors Inc. boosted its holdings in Incyte by 2.2% in the 1st quarter. Pacer Advisors Inc. now owns 1,741,061 shares of the biopharmaceutical company’s stock worth $163,869,000 after buying an additional 37,790 shares during the period. Finally, Legal & General Group Plc bought a new stake in Incyte during the 2nd quarter valued at $182,054,000. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Incyte Stock Performance

Shares of Incyte stock opened at $116.80 on Friday. Incyte Corporation has a 52-week low of $89.25 and a 52-week high of $132.60. The company has a fifty day moving average of $120.62 and a 200-day moving average of $108.07. The stock has a market capitalization of $23.68 billion, a price-to-earnings ratio of 14.88, a price-to-earnings-growth ratio of 4.83 and a beta of 0.74.

Incyte (NASDAQ:INCY) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, topping analysts’ consensus estimates of ($3.93) by $0.33. Incyte had a net margin of 27.71% and a return on equity of 29.93%. The company had revenue of $1.56 billion for the quarter, compared to analysts’ expectations of $1.46 billion. During the same quarter last year, the company earned $2.26 EPS. The firm’s revenue was up 14.0% compared to the same quarter last year. On average, equities research analysts forecast that Incyte Corporation will post 1.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Citigroup reiterated a “buy” rating on shares of Incyte in a research report on Monday, August 3rd. Zacks Research downgraded shares of Incyte from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Benchmark reaffirmed a “buy” rating on shares of Incyte in a report on Tuesday, October 13th. JPMorgan Chase & Co. boosted their target price on Incyte from $120.00 to $123.00 and gave the stock a “neutral” rating in a research report on Monday, September 28th. Finally, HC Wainwright restated a “buy” rating on shares of Incyte in a research report on Tuesday. Twelve research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $131.43.

Insider Buying and Selling

In other Incyte news, insider Pablo Cagnoni sold 10,801 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $125.56, for a total value of $1,356,173.56. Following the completion of the sale, the insider owned 183,200 shares in the company, valued at approximately $23,002,592. The trade was a 5.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 16.20% of the stock is owned by company insiders.

Key Headlines Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Third-quarter revenue rose 14% year over year to $1.56 billion, exceeding the roughly $1.46 billion analyst estimate. The adjusted loss of $3.60 per share was also narrower than expected, reflecting solid underlying business performance. Incyte Reports Q3 Loss, Beats Revenue Estimates
• Positive Sentiment: Incyte raised its 2026 total net-sales guidance to $5.21 billion-$5.30 billion, from $5.13 billion-$5.26 billion previously. Opzelura guidance increased to $1.10 billion-$1.12 billion, supported by strong demand. Incyte Raises 2026 Sales Outlook
• Positive Sentiment: Key products performed well: Opzelura sales increased 36% to $255 million, Hematology and Oncology portfolio sales rose 38% to $235 million, and Jakafi and Jakafi XR sales grew 4% to $827 million. Incyte Third-Quarter Revenue and Guidance Update
• Positive Sentiment: Pipeline sentiment also improved after early data characterized Incyte’s G12D program as competitive in pancreatic cancer, while a partner began a Phase 1 study combining INCA33890 with another therapy in colorectal cancer. Incyte G12D Pipeline Update
• Neutral Sentiment: Management’s earnings call highlighted $3.9 billion in cash, cash equivalents and marketable securities at quarter-end, providing financial flexibility for development and acquisitions. Incyte Q3 Earnings Call Transcript
• Negative Sentiment: Incyte reported a GAAP net loss of approximately $785 million, or $3.86 per share, versus a profit in the prior-year quarter. The result was primarily driven by a $1.23 billion in-process research and development charge tied to the Vega Therapeutics acquisition. Incyte Q3 Loss and Vega Acquisition Charge
• Negative Sentiment: Although guidance was raised, some investors viewed the new full-year sales range as below the level implied by consensus expectations, limiting the positive reaction to the earnings beat.

About Incyte

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.